Sanofi CFO Jerome Con­t­a­mine hits the ex­it; Strug­gling Fi­bro­cell trig­gers a strate­gic re­view

→ Pen­ny stock biotech Fi­bro­cell Sci­ence $FC­SC is wav­ing the white flag. Ex­ecs have be­gun a strate­gic re­view for the com­pa­ny, and every­thing is on the ta­ble. The gene ther­a­py com­pa­ny based in Ex­ton, PA is open to a sale or re­verse merg­er for any­one look­ing for a short cut to Nas­daq. It wouldn’t be ex­pen­sive. The biotech’s mar­ket cap has dwin­dled to $17 mil­lion.

→ Sanofi is prepar­ing for the re­tire­ment of  CFO Jerome Con­t­a­mine, who’s leav­ing the French drug­mak­er af­ter al­most 10 years in the role. Be­fore he leaves lat­er this year, the com­pa­ny says, Con­t­a­mine will help iden­ti­fy a suc­ces­sor and guide the tran­si­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER